doi:10.3969/j.issn.1671-2587.2023.02.003

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2023, Vol. 25 ›› Issue (2): 170-179.DOI: 10.3969/j.issn.1671-2587.2023.02.003

Previous Articles Next Articles

Received:2023-01-11 Published:2023-04-25

[1] Mark K Fung.Cohn.AABB Technical Manual(18th edition)[M].Bethesda, MD:AABB Press,2018.
[2] Mark K Fung.Cohn.AABB Technical Manual(19th edition)[M].Bethesda, MD:AABB Press,2019.
[3] Claudia S.Cohn.AABB Technical Manual(20th edition)[M].Bethesda, MD:AABB Press,2020.
[4] Food and Drug Administration.Guidance for industry: Revised recommendations for reducing the risk of Zika virus transmission by blood and blood components[EB/OL].(2018-07).https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/blood-guidances.
[5] Eder AF.Donor reentry.In: Eder AF, Goldman M, eds.Screening blood donors with the donor history questionnaire[M].Bethesda, MD:AABB Press, 2019:209-47.
[6] International Society of Blood Transfusion.Red Cell Immunogenetics and Blood Group Terminology (working group)[EB/OL].(2022-11-20).https://www.isbtweb.org/isbt-working-parties/rcibgt.html.
[7] YOUNG P P,COTTON B A,GOODNOUGH L T.Massive transfusion protocols for patients with substantial hemorrhage[J].Transfus Med Rev,2011,25(4):293-303.
[8] HENDRICKSON J E,SHAZ B H,PEREIRA G,et al.Implementation of a pediatric trauma massive transfusion protocol:one institution’s experience[J].Transfusion,2012,52(6):1228-1236.
[9] STANSBURY L G,DUTTON R P,STEIN D M,et al.Controversy in trauma resuscitation:do ratios of plasma to red blood cells matter?[J].Transfus Med Rev,2009,23(4):255-265.
[10] CALLUM J L,NASCIMENTO B,TIEN H,et al.Editorial:“formula-driven” versus “lab-driven” massive transfusion protocols:At a state of clinical equipoise[J].Transfus Med Rev,2009,23(4):247-254.
[11] HOLCOMB J B,DEL JUNCO D J,FOX E E,et al.The prospective,observational,multicenter,major trauma tran-sfusion (PROMMTT) study:comparative effectiveness of a time-varying treatment with competing risks[J].JAMA Surg,2013,148(2):127-136.
[12] PAULL B.Transfusion of plasma,platelets,and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma:the PROPPR randomized clinical trial[J].J Emerg Med,2015,49(1):122.
[13] SPERRY J L,GUYETTE F X,BROWN J B,et al.Prehospital plasma during air medical transport in trauma patients at risk for hemorrhagic shock[J].N Engl J Med,2018,379(4):315-326.
[14] DZIK W S,ZIMAN A,COHN C,et al.Survival after ultramassive transfusion:a review of 1360 cases[J].Transfusion,2016,56(3):558-563.
[15] JOHNSON D J,SCOTT A V,BARODKA V M,et al.Morbidity and mortality after high-dose transfusion[J].Anesthesiology,2016,124(2):387-395.
[16] ROSSAINT R,BOUILLON B,CERNY V,et al.The European guideline on management of major bleeding and coagulopathy following trauma:fourth edition[J].Crit Care,2016,20:100.
[17] CHANDLER M H,ROBERTS M,SAWYER M,et al.The US military experience with fresh whole blood during the conflicts in Iraq and Afghanistan[J].Semin Cardiothorac Vasc Anesth,2012,16(3):153-159.
[18] CAP A P,BECKETT A,BENOV A,et al.Whole blood transfusion[J].Mil Med,2018,183(suppl_2):44-51.
[19] YAZER M H,CAP A P,SPINELLA P C,et al.How do I implement a whole blood program for massively bleeding patients?[J].Transfusion,2018,58(3):622-628.
[20] YAZER M H,SPINELLA P C.The use of low-titer group O whole blood for the resuscitation of civilian trauma patients in 2018[J].Transfusion,2018,58(11):2744-2746.
[21] SEHEULT J N,BAHR M,ANTO V,et al.Safety profile of uncrossmatched,cold-stored,low-titer,group O+ whole blood in civilian trauma patients[J].Transfusion,2018,58(10):2280-2288.
[22] STUBBS J R,TRAN S A,EMERY R L,et al.Cold platelets for trauma-associated bleeding:regulatory approval,accreditation approval,and practice implementation-just the tip of the iceberg[J].Transfusion,2017,57(12):2836-2844.
[23] SEHEULT J N,ANTO V,ALARCON L H,et al.Clinical outcomes among low-titer group O whole blood recipients compared to recipients of conventional components in civilian trauma resuscitation[J].Transfusion,2018,58(8):1838-1845.
[24] GAMMON R, ed.Standards for blood banks and transfusion services.32nd ed[M].Bethesda, MD: AABB, 2020.
[25] CURLEY A,STANWORTH S J,WILLOUGHBY K,et al.Randomized trial of platelet-transfusion thresholds in neonates[J].N Engl J Med,2019,380(3):242-251.
[26] SOLA-VISNER M C.Platelet transfusions in neonates - less is more[J].N Engl J Med,2019,380(3):287-288.
[27] MONAGLE P,BARNES C,IGNJATOVIC V,et al.Developmental haemostasis.Impact for clinical haemostasis laboratories[J].Thromb Haemost,2006,95(2):362-372.
[28] COWMAN J,QUINN N,GEOGHEGAN S,et al.Dynamic platelet function on von Willebrand factor is different in preterm neonates and full-term neonates:changes in neonatal platelet function[J].J Thromb Haemost,2016,14(10):2027-2035.
[29] HOGLE L F,DAS A.The social production of evidence:regenerative medicine and the 21st Century Cures Act[J].Regen Med,2017,12(6):581-586.
[30] ATKINS J W,WEST K,KASOW K A.Current and future cell therapy standards and guidelines[J].Oncol Clin N Am,2019,33(5):839-855.
[31] GOLCHIN A,FARAHANY T Z.Biological products:cellular therapy and FDA approved products[J].Stem Cell Rev Rep,2019,15(2):166-175.
[32] EL-HAKIM EL-KADIRY A,RAFEI M,SHAMMAA R.Cell therapy:types,regulation,and clinical benefits[J].Front Med,2021,8:756029.
[33] ZHANG X M,ZHU L L,ZHANG H,et al.CAR-T cell therapy in hematological malignancies:current opportunities and challenges[J].Front Immunol,2022,13:927153.
[34] NEELAPU S S,LOCKE F L,BARTLETT N L,et al.Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma[J].N Engl J Med,2017,377(26):2531-2544.
[35] ABRAMSON JS.Anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma[J].Transfus Med Rev,2020,34(1):29-33.
[36] DAI H R,WU Z Q,JIA H J,et al.Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia[J].J Hematol Oncol,2020,13(1):1-10.
[37] WANG M,MUNOZ J,GOY A,et al.KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma[J].N Engl J Med,2020,382(14):1331-1342.
[38] SHAH B D,GHOBADI A,OLUWOLE O O,et al.KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia:phase 2 results of the single-arm,open-label,multicentre ZUMA-3 study[J].Lancet,2021,398(10299):491-502.
[39] MUNSHI N C,ANDERSON L D Jr,SHAH N,et al.Idecabtagene vicleucel in relapsed and refractory multiple myeloma[J].N Engl J Med,2021,384(8):705-716.
[40] ANDERSON L D Jr.Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma[J].Future Oncol,2022,18(3):277-289.
[41] RAJE N,BERDEJA J,LIN Y,et al.Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma[J].N Engl J Med,2019,380(18):1726-1737.
[42] CORTÉS-HERNÁNDEZ A,ALVAREZ-SALAZAR E K,SOLDEVILA G.Chimeric antigen receptor (CAR) T cell therapy for cancer.challenges and opportunities:an overview[J].Methods Mol Biol,2021,2174:219-244.
[43] STERNER R C,STERNER R M.CAR-T cell therapy:current limitations and potential strategies[J].Blood Cancer J,2021,11(4):69.
[44] HASLAUER T,GREIL R,ZABORSKY N,et al.CAR T-c ell therapy in hematological malignancies[J].Int J Mol Sci,2021,22(16):8996.
[45] HUANG J W,HUANG X B,HUANG J.CAR-T cell therapy for hematological malignancies:limitations and optimization strategies[J].Front Immunol,2022,13:1019115.
[46] LIU Q Z,LIU Z P,WAN R X,et al.Clinical strategies for enhancing the efficacy of CAR T-cell therapy for hematological malignancies[J].Cancers,2022,14(18):4452.
[47] HOLSTEIN S A,LUNNING M A.CAR T-cell therapy in hematologic malignancies:a voyage in progress[J].Clin Pharmacol Ther,2020,107(1):112-122.
[48] MI J Q,XU J,ZHOU J F,et al.CAR T-cell immunotherapy:a powerful weapon for fighting hematological B-cell malignancies[J].Front Med,2021,15(6):783-804.
[49] PAN K,FARRUKH H,CHITTEPU V C S R,et al.CAR race to cancer immunotherapy:from CAR T,CAR NK to CAR macrophage therapy[J].J Exp Clin Cancer Res,2022,41(1):1-21.
[50] BIEDERSTÄDT A,REZVANI K.Engineering the next generation of CAR-NK immunotherapies[J].Int J Hematol,2021,114(5):554-571.
[51] XIE G Z,DONG H,LIANG Y,et al.CAR-NK cells:a promising cellular immunotherapy for cancer[J].eBioMedicine,2020,59:102975.
[52] WANG W,JIANG J,WU C,et al.CAR-NK for tumor immunotherapy: clinical transformation and future prospects[J].Cancer Lett,2020,472:175-180.
[53] ALBINGER N,HARTMANN J,ULLRICH E.Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany[J].Gene Ther,2021,28(9):513-527.
[54] VAHIDIAN F,KHOSROSHAHI L M,AKBARZADEH M,et al.The tricks for fighting against cancer using CAR NK cells:a review[J].Mol Cell Probes,2022,63:101817.
[55] LIU E L,MARIN D,BANERJEE P,et al.Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors[J].N Engl J Med,2020,382(6):545-553.
[56] WRONA E,BOROWIEC M,POTEMSKI P.CAR-NK cells in the treatment of solid tumors[J].Int J Mol Sci,2021,22(11):5899.
[57] CAO B H,LIU M T,HUANG J J,et al.Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer[J].Int J Biol Sci,2021,17(14):3850-3861.
[58] HAN J F,CHU J H,KEUNG CHAN W,et al.CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells[J].Sci Rep,2015,5:11483.
[59] HU Z W.Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer[J].Sci Rep,2020,10:2815.
[60] LEE Y E,JU A N,CHOI H W,et al.Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment[J].J Control Release,2020,326:310-323.
[61] CAO B H,LIU M T,WANG L,et al.Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer[J].Biochem Biophys Res Commun,2020,524(1):96-102.
[62] AO X,YANG Y,LI W Q,et al.Anti-αFR CAR-engineered NK-92 cells display potent cytotoxicity against αFR-positive ovarian cancer[J].J Immunother,2019,42(8):284-296.
[63] CALLUM J L,WATERS J H,SHAZ B H,et al.The AABB recommendations for the Choosing Wisely campaign of the American Board of Internal Medicine[J].Transfusion,2014,54(9):2344-2352.
[64] JONES J M,SAPIANO M R P,SAVINKINA A A,et al.Slowing decline in blood collection and transfusion in the United States - 2017[J].Transfusion,2020,60(Suppl 2):S1-S9.
[65] AABB.The 2016 AABB Blood Survey Fact Sheet[EB/OL].(2020-03-26)http://www.aabb.org/research/hemovigilance/bloodsurvey/Pages/default.Aspx.
[66] DE VRIES R R P,FABER J C.Hemovigilance:An Effective Tool for Improving Transfusion Safety[M].UK:Wiley,2012.
[67] CHUNG K W,HARVEY A,BASAVARAJU S V,et al.How is national recipient hemovigilance conducted in the United States?[J].Transfusion,2015,55(4):703-707.
[68] MENIS M,ANDERSON S A,FORSHEE R A,et al.Transfusion-related acute lung injury and potential risk factors among the inpatient US elderly as recorded in Medicare claims data,during 2007 through 2011[J].Transfusion,2014,54(9):2182-2193.
[69] JOHN P,Nolan,.Suspension array technology:evolution of the flat-array paradigm[J].Trends Biotechnol,2002,20(1):9-12.
[70] LANE W J,WESTHOFF C M,UY J M,et al.Comprehensive red blood cell and platelet antigen prediction from whole genome sequencing:proof of principle[J].Transfusion,2016,56(3):743-754.
[71] WILLIAM J,Lane,MD,et al.Automated typing of red blood cell and platelet antigens:a whole-genome sequencing study[J].Lancet Haematol,2018,5(6):e241-e251.
[72] FICHOU Y,AUDRÉZET M P,GUÉGUEN P,et al.Next-generation sequencing is a credible strategy for blood group genotyping[J].Br J Haematol,2014,167(4):554-562.
[73] MCBEAN RS, HYLAND CA, FLOWER RL.Approaches to determination of a full profile of blood group genotypes:single nucleotide variant mapping and massively parallel sequencing[J].Comput Struct Biotechnol J,2014,11(19):147-151.
[74] WAGNER F F.RHD PCR of D-negative blood donors[J].Transfus Med Hemother,2013,40(3):172-181.
[75] PHAM B N,PEYRARD T,TOURRET S,et al.Anti-HrB and anti-hrb revisited[J].Transfusion,2009,49(11):2400-2405.
[76] REID M E,HIPSKY C H,VELLIQUETTE R W,et al.Molecular background of RH in Bastiaan,the RH:-31,-34 index case,and two novel RHD alleles[J].Immunohematology,2012,28(3):97-103.
[77] KELLER MA, HORN T, CROWLEY J, et al.Genotype compatibility tables for matching patients and donors for RH variants[J].Transfusion,2013,53(2S): 174A.
[78] NAY W.Hyperhemolysis syndrome in sickle cell disease[J].Expert Rev Hematol,2009,2(2):111-115.
[79] CHONAT S,QUARMYNE M O,BENNETT C M,et al.Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease[J].Haematologica,2018,103(10):e483-e485.
[80] DUMAS G,HABIBI A,ONIMUS T,et al.Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients[J].Blood,2016,127(8):1062-1064.
[81] WIN N, SINHA S, LEE E, MILLS W.Treatment with intravenous immunoglobulin and steroids may correct severe Anemia in hyperhemolytic transfusion reactions:case report and literature review[J].Transfus Med Rev,2010,24(1):64-67.
[82] PIRENNE F,YAZDANBAKHSH K.How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions[J].Blood,2018,131(25):2773-2781.
[83] MEKONTSO DESSAP A,PIRENNE F,RAZAZI K,et al.A diagnostic nomogram for delayed hemolytic transfusion reaction in sickle cell disease[J].Am J Hematol,2016,91(12):1181-1184.
[84] HABIBI A,MEKONTSO-DESSAP A,GUILLAUD C,et al.Delayed hemolytic transfusion reaction in adult sickle-cell disease:presentations,outcomes,and treatments of 99 referral center episodes[J].Am J Hematol,2016,91(10):989-994.
[85] VIDLER J B,GARDNER K,AMENYAH K,et al.Delayed haemolytic transfusion reaction in adults with sickle cell disease:a 5-year experience[J].Br J Haematol,2015,169(5):746-753.
[86] PADMANABHAN A,CONNELLY-SMITH L,AQUI N,et al.Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis:the eighth special issue[J].J Clin Apher,2019,34(3):171-354.
[87] BOADA M,LÓPEZ O L,OLAZARÁN J,et al.A randomized,controlled clinical trial of plasma exchange with albumin replacement for Alzheimer’s disease:primary results of the AMBAR Study[J].Alzheimers Dement,2020,16(10):1412-1425.
[88] NAKATSUJI Y.Therapeutic apheresis in neurological disorders[J].Brain Nerve,2021,73(5):425-430.
[89] SZCZEPIORKOWSKI Z M.Indications for therapeutic apheresis in hematological disorders[J].Semin Hematol,2020,57(2):57-64.
[90] CHEN Y Y,SUN X,HUANG W,et al.Therapeutic apheresis in kidney diseases:an updated review[J].Ren Fail,2022,44(1):842-857.
[91] PANDEY P,SETYA D,SINHA V,et al.Therapeutic apheresis in ABO-incompatible kidney and liver transplantation:a single-center experience of 50 patients[J].Ther Apher Dial,2021,25(1):103-117.
[92] DUAN W,ZHOU H,DONG X,et al.Application of lymphoplasmapheresis in the treatment of severe myasthenia gravis[J].Front Neurol,2022,13:1018509.
[93] OUYANG S,YIN W F,ZENG Q M,et al.Lymphoplasma exchange improves myasthenia gravis exacerbations:a retrospective study in a Chinese center[J].Front Immunol,2022,13:757841.
[94] WANG B,LI J,XIE H F,et al.Striking case of Febrile ulceronecrotic Mucha-Habermann disease responding to lymphoplasmapheresis and methotrexate[J].J Dermatol,2020,47(12):e430-e431.
[95] ZHANG Z M,YUAN X,JIANG Y J,et al.Effectiveness of lymphoplasmapheresis compared with therapeutic plasma exchange for thrombotic thrombocytopenic purpura:a retrospective evaluation[J].Hematology,2022,27(1):167-172.
[96] ZHANG Z,SHEN Y,SHU X,et al.Successful whole-blood exchange transfusion in a patient with paroxysmal nocturnal hemoglobinuria:a case report and literature review[J].J Int Med Res,2019,47(9):4562-4567.
[97] Food and Drug Administration.Guidance for Industry: Revised recommendations to reduce the risk of transfusion-transmitted malaria[EB/OL].(2020-04).https://www.fda.gov/regulatory-information/search-fda-guidance-documents/revised-recommendations-reduce-risktransfusion-transmitted-malaria.
[98] Food and Drug Administration.Guidance for Industry: Revised recommendations to reduce the risk of human immunodeficiency virus transmission by blood and blood products[EB/OL].(2020-04).https://www.fda.gov/regulatory-information/search-fda-guidance-documents/revised-recommendations-reducing-risk-humanimmunodeficiency-virus-transmission-bloodand-blood.
[99] CID J,ESCOLAR G,GALAN A N,et al.In vitro evaluation of the hemostatic effectiveness of cryopreserved platelets[J].Transfusion,2016,56(3):580-586.
[100] VALERI C R,RAGNO G,KHURI S.Freezing human platelets with 6 percent dimethyl sulfoxide with removal of the supernatant solution before freezing and storage at-80 degrees C without postthaw processing[J].Transfusion,2005,45(12):1890-1898.
[101] NAIR P M,PIDCOKE H F,CAP A P,et al.Effect of cold storage on shear-induced platelet aggregation and clot strength[J].J Trauma Acute Care Surg,2014,77(3 Suppl 2):S88-S93.

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

About

Author

Journal

Access Statistics

Contact

[1]	. [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 180-184.
[2]	FAN Feng-yan, MA Yue-yun. The Selection of RhD Blood Type in Blood Transfusion of RhD Mismatched Allogeneic Hematopoietic Stem Cell Transplantation [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 189-192.
[3]	YUAN Hai-qing, JING Hong-li, ZHU Li-li, et al. Discussion on the Current Situation of Red Blood Cell Component Blood Inventory Management in 26 Local and Municipal Blood Stations in China [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 204-209.
[4]	XU Lan, GUO He-long, ZHU Li-li, et al. Productivity Analysis of Red Blood Cell Products in 20 Central Blood Stations in China [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 210-214.
[5]	WANG Rui-han, PENG Juan, LIU Hao, et al. Effects of Intraoperative Cell Salvage on Coagulation and Fetal Components in High-risk Cesarean Section [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 215-219.
[6]	HU Yi-fan, HUANG Li-ping, LIU Yi-quan. Video Stimulation Test Prevents the Vagus Nerve Reaction Related to Blood Donation Caused by Anxiety [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 230-234.
[7]	ZHU Yu-li, AN Run, FENG Zhi-hui. Identification of Rare Di(b-) Blood Group by TaqMan-MGB Real-time PCR [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 235-238.
[8]	. [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 273-276.
[9]	GE Shuang, WANG De-qing. Research Advances in Transfusion Medicine 2021-2022 [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 276-281.
[10]	QING Yun, ZHOU Qiong, PENG Kai, et al. Performances of Platelet Storage in SSP+ Additive Solution versus Plasma [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(6): 698-704.
[11]	MAO Ping-ping, WANG Shu-jun, LUO Kai-yun, et al. Study on the Antibacterial Effect of Frozen Platelet-rich Plasma and Lyophilized Platelet-rich Plasma [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(6): 705-709.
[12]	CHEN Rui, LV Meng-xing, YIN Jia-zhong, et al. The Transfusion Management in Children with Thalassemia：Safety Strategies in Yunnan Province [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(6): 710-715.
[13]	XIE Hui-yi, ZHOU Zai-xin, YANG Yue, et al. Analysis of the Influence of Anti-M Antibody on Blood Group Identification and Clinical Blood Transfusion [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(6): 716-720.
[14]	HU Heng-ya, ZHOU Xiao-yu. The Effect of Preoperative Anemia on Perioperative Transfusion and Postoperative Outcomes in Children with Congenital Heart Disease [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(6): 721-724.
[15]	. [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(6): 730-735.